PBS dispute could see MS patients pay thousands for crucial drugs Ocrevus and Kesimpta
A dispute over how Australia prices medicines has sparked fears 10,000 people with multiple sclerosis will be forced…
Swiss firms invest US$27bil after tariff deal
ZURICH: Swiss companies invested US$27bil in the United States between January and April, as Switzerland moves to fulfil…
Global drug makers face pricing pressure as China targets affordable healthcare
Global pharmaceutical companies posted mixed earnings in China last year, with some firms warning that 2026 will be…
Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial – Endpoints News
Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial Endpoints News Roche unveils data behind BTK inhibitor’s phase…
Shanghai to scrap all foreign investment limits on manufacturing facilities
Mainland China’s commercial and financial hub Shanghai has pledged to remove all regulatory hurdles for foreign investors to…
First new antibiotic in 50 years to tackle superbug
The first new antibiotic in 50 years to tackle a common superbug will be tested on patients. The…